Direxion Daily S&P Biotech Bull 3X ETF
LABU
40 hedge funds and large institutions have $44.4M invested in Direxion Daily S&P Biotech Bull 3X ETF in 2025 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 10 closing their positions.
0% more funds holding
Funds holding: 40 → 40 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
2% less call options, than puts
Call options by funds: $145M | Put options by funds: $148M
3.95% less ownership
Funds ownership: 7.3% → 3.35% (-4%)
22% less capital invested
Capital invested by funds: $56.9M → $44.4M (-$12.5M)
53% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 15
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.25M |
| 2 |
GS
GTS Securities
Miami,
Florida
|
+$1.44M |
| 3 |
Barclays
London,
United Kingdom
|
+$769K |
| 4 |
FIA
Foundations Investment Advisors
Phoenix,
Arizona
|
+$687K |
| 5 |
SH
SLT Holdings
Scottsdale,
Arizona
|
+$687K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$12.6M |
| 2 |
Squarepoint
New York
|
-$10.1M |
| 3 |
Morgan Stanley
New York
|
-$5.03M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.82M |
| 5 |
JP Morgan Chase
New York
|
-$4M |
LABU Hedge Fund Activity: Q4 2025 in Review
40 of the 8,274 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bull 3X ETF (LABU) for Q4 2025, worth a combined $44.4M — down 22% from $56.9M a quarter earlier.
Fund positioning in LABU was balanced in Q4 2025: 10 funds opened new positions, 10 closed out, 7 added to existing stakes and 15 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $2.25M. The largest seller was Citadel Advisors, exiting entirely with an estimated $12.6M sold.
- 40 institutional investors held Direxion Daily S&P Biotech Bull 3X ETF (LABU) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $44.4M of Direxion Daily S&P Biotech Bull 3X ETF stock for Q4 2025, down 22% quarter-over-quarter.
- 10 funds opened new Direxion Daily S&P Biotech Bull 3X ETF positions in Q4 2025 and 10 closed out, a net change of 0 holders.
- The largest Direxion Daily S&P Biotech Bull 3X ETF buyer in Q4 2025 was Susquehanna International Group, an estimated $2.25M added.
- The largest Direxion Daily S&P Biotech Bull 3X ETF seller in Q4 2025 was Citadel Advisors, an estimated $12.6M sold.
Based on aggregated 13F filings for Q4 2025.